Touch Medical Media coverage of data presented at EADV 2021:
Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) kindly took the time to speak to us about the health burden of prurigo and recent investigations into the IL-31 targeted therapy, nemolizumab.
Her presentation entitled ‘Nemolizumab rapidly relieves itch and sleep disturbances in patients with prurigo nodularis’ was given at the EADV 30th Congress, 29 Sep – 2 Oct.
Questions
- Could you tell us a little about prurigo nodularis and its health burden? (0:11)
- Why has interleukin-31 become a clinical target for chronic pruritus and prurigo treatment? (0:59)
- What were the aims and design of the clinical study you are presenting? (1:45)
- What were the clinical endpoints and how well were these achieved? (2:24)
- Could you tell us a little about the safety profile of nemolizumab? (2:54)
Disclosures: Prof. Sonja Ständer has received consultancy, advisory board and speaker fees from Galderma and also acted as an investigator for Galderma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
